Alexion Pharmaceuticals, Inc. (ALXN) Financial Statements (2025 and earlier)

Company Profile

Business Address 121 SEAPORT BOULEVARD
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2,2972,8522,3632,7502,216
Cash and cash equivalent 2,2682,8252,3152,6862,171
Short-term investments 2927486444
Receivables 1,4371,3721,3451,2431,116
Inventory, net of allowances, customer advances and progress billings 861578587628577
Inventory 861578587628577
Other current assets 605566575456433
Other undisclosed current assets (132)    
Total current assets: 5,0685,3684,8705,0764,341
Noncurrent Assets
Operating lease, right-of-use asset 220210203  
Property, plant and equipment 1,2151,1961,1601,1631,148
Intangible assets, net (including goodwill) 8,1577,1359,2608,3828,448
Goodwill 5,1015,0755,0725,0375,037
Intangible assets, net (excluding goodwill) 3,0572,0604,1883,3443,410
Restricted cash and investments     00
Deferred income tax assets 2,2712,3322,224  
Other noncurrent assets 618462432429671
Other undisclosed noncurrent assets     2,494207
Total noncurrent assets: 12,48111,33513,27812,46810,474
TOTAL ASSETS: 17,54816,70318,14917,54514,815
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 1,068862863967868
Taxes payable     104 
Employee-related liabilities     191 
Accounts payable 89    
Accrued liabilities 978  201 
Other undisclosed accounts payable and accrued liabilities   862863471868
Debt 139127127127127
Business combination, contingent consideration, liability      
Other liabilities 12513213010196
Total current liabilities: 1,3311,1201,1201,1941,091
Noncurrent Liabilities
Long-term debt and lease obligation 2,6292,4812,5062,3752,407
Long-term debt, excluding current maturities 2,4532,3122,3432,3752,407
Liabilities, other than long-term debt 2,5132,6112,775293468
Deferred income tax liabilities 1,8181,9472,113  
Liability, pension and other postretirement and postemployment benefits     28 
Other liabilities 297290303266280
Operating lease, liability 176169163  
Business combination, contingent consideration, liability 398375359 188
Other undisclosed noncurrent liabilities     2,410482
Total noncurrent liabilities: 5,1435,0925,2815,0793,357
Total liabilities: 6,4746,2126,4016,2734,448
Equity
Equity, attributable to parent 11,07510,49111,74811,27210,367
Treasury stock, value (2,544)(2,470)(2,213)(2,106)(2,073)
Additional paid in capital 9,0308,9428,8658,8058,738
Accumulated other comprehensive loss (119)(111)(102)(67)(48)
Retained earnings 4,7074,1295,1974,6403,751
Equity, attributable to noncontrolling interest      
Total equity: 11,07510,49111,74811,27210,367
TOTAL LIABILITIES AND EQUITY: 17,54816,70318,14917,54514,815

Income Statement (P&L) ($ in millions)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Revenues(4,478)1,5891,4451,4451,3841,263
Cost of revenue (163)(159)(116)(114)(95)
Cost of product and service sold (145)(145)(112)(114)(95)
Gross profit: 1,4261,2861,3291,2701,168
Operating expenses (741)(2,656)(634)(729)(638)
Operating income (loss): 685(1,370)696541530
Nonoperating income (expense) 1042(6)8323
Investment income, nonoperating 1242(5)5023
Other nonoperating income (expense) (2)0(1)330
Interest and debt expense (28)(24)(26)(22)(18)
Income (loss) from continuing operations before income taxes: 667(1,352)664602536
Income tax expense (benefit) (89)284(106)287(68)
Income (loss) from continuing operations: 578(1,068)558889468
Income (loss) before gain (loss) on sale of properties:578(1,068)558889468
Net income (loss): 578(1,068)558889468
Net income attributable to noncontrolling interest      
Net income (loss) available to common stockholders, diluted: 578(1,068)558889468

Comprehensive Income ($ in millions)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Net income (loss): 578(1,068)558889468
Other undisclosed comprehensive income    10 
Comprehensive income (loss): 578(1,068)558899468
Comprehensive income, net of tax, attributable to noncontrolling interest      
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (8)(9)(35)(29)10
Comprehensive income (loss), net of tax, attributable to parent: 570(1,078)523870477

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: